This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Chinese embassy replies to proposed US tariffs, cites mutual benefits of trade cooperation

( November 26, 2024, 07:13 GMT | Official Statement) -- MLex Summary: Liu Pengyu, spokesman for the Chinese Embassy in the US, said that "China-US economic and trade cooperation is mutually beneficial in nature. No one will win a trade war or tariff war," according to China's state-run CCTV. His remarks were made in response to US President-elect Donald Trump's plan to impose an additional 10 percent tariff on all Chinese imports, citing the flow of illegal drugs into the US, particularly fentanyl, a leading cause of drug overdoses in the US. Liu stressed "the idea that China knowingly allowing fentanyl precursors runs completely counter to facts and reality," and highlighted China's cooperation with US law enforcement and case-verification requests against narcotics since the 2023 San Francisco Summit between the leaders of the two countries.The statement follows:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections